返回搜索用邮件客户端发送给 Clinical.Trials@bms.com
正在招募III 期编号 NCT06929273
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
报名条件(概要)
- 年龄:18 Years – 65 Years
- 性别:不限
- 健康志愿者:不接受
完整入排标准请以官方页面为准。
开展国家/地区
United States、Argentina、Australia、Bulgaria、China、Croatia、Denmark、France、Hungary、India、Israel、Italy
研究药物 / 干预措施
KarXT、Lithium、Valproate、Lamotrigine
申办方
Bristol-Myers Squibb
研究简介(原文)
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
适应症
Bipolar Disorder Type I With Mania
主动联系研究团队
总联系人(申办方/研究总部)
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.comClinical.Trials@bms.com855-907-3286
研究中心联系方式
- Pillar Clinical Research - RichardsonBentonville,Arkansas,United States
- Pillar Clinical Research- Little RockLittle Rock,Arkansas,United States
- Woodland International Research GroupLittle Rock,Arkansas,United States
- Woodland Research NorthwestRogers,Arkansas,United States
- Advanced Research Center Inc.Anaheim,California,United States
- Clinical Innovations, Inc. dba CITrialsBellflower,California,United States
问自己是否符合条件、如何预筛
我的病情档案
档案只保存在您自己的浏览器里,不会上传,任何人(包括本站)都看不到。
英文版(发给研究团队)
Dear Study Team, I am a patient in China and I am interested in participating in your clinical trial: Study Title: A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) ClinicalTrials.gov Identifier: NCT06929273 Sponsor: Bristol-Myers Squibb Investigational product: KarXT, Lithium, Valproate, Lamotrigine About me: - Age: (please fill in) - Sex: (please fill in) - Confirmed diagnosis and stage: (please fill in) - Biomarkers / genetic testing: not available - Prior and current treatments: (please fill in) - Performance status (ECOG): not assessed - Current location: China - Travel ability: (please fill in) Could you please let me know: 1. Whether I might be eligible for this study; 2. Which site would be closest and most practical for me, and whether remote pre-screening is possible; 3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening. I can provide English translations of my medical records. Thank you very much for your time and help. Kind regards, (your name) (your email / phone with country code)
中文对照(供您核对)
尊敬的研究团队: 我是一位来自中国的患者,希望咨询参加以下临床试验的可能: 研究名称:A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) 试验编号:NCT06929273 申办方:Bristol-Myers Squibb 研究药物:KarXT、Lithium、Valproate、Lamotrigine 我的基本情况: - 年龄:(请填写) - 性别:(请填写) - 确诊疾病与分期:(请填写) - 基因/标志物检测:暂无 - 既往及当前治疗:(请填写) - 体能状态(ECOG):未评估 - 目前所在城市:中国 - 可前往范围:(请填写) 想请教三个问题: 1. 我是否可能符合本研究的入组标准? 2. 哪个中心对我最方便可行?能否远程预筛? 3. 预筛需要准备哪些资料(病历、病理、影像、近期化验)? 我可以提供英文翻译版病历。感谢您的时间与帮助。 顺祝安康 (您的姓名) (您的邮箱/带国际区号的电话)
提示:请与主治医生一起发信——由医生署名的申请,回复率远高于患者单独发信。首封邮件不要附身份证号等敏感信息。研究团队通常在 3–10 个工作日内回复,两周无回音可礼貌追问一次。
下一步怎么做?
- 把本页信息带给您的主治医生,评估是否适合参加。
- 点击下方按钮打开官方注册页,查看研究中心联系方式。
- 直接联系研究团队咨询报名事宜(通常有中文同声翻译服务可协助沟通)。